Earnings Releases·Nov 12, 2026, 7:19 AM ET

Twist Bioscience — Fiscal 2026 Earnings Summary

Fiscal 2026 revenue reached a record $459.4 million (up 22% YoY), driven by 28% Q4 growth to $126.6 million and 15 consecutive quarters of sequential revenue expansion.
Gross margin improved to 52.4% for the full year and 53.1% in Q4, while adjusted EBITDA turned positive in Q4 at $2.2 million compared to a loss in the prior year.
Fiscal 2027 guidance projects revenue of $550–$560 million (approx. 21% growth) and positive adjusted EBITDA, with $100 million of revenue attributed to AI drug discovery.
The company raised approximately $425 million in net proceeds via equity offerings and plans $75 million in capital expenditures for fiscal 2027 as part of a two-year investment plan.
Both business segments (DSPS and NGS) posted double-digit growth, with total customers increasing to 4,100 and physical shipments rising to 1.3 million genes.